How semaglutides cause weight loss: the biology behind the results

You eat less — but not because you are trying harder

Imagine sitting down to dinner and realising, about halfway through, that you genuinely have no interest in finishing. Not because you are disciplining yourself, the appetite simply is not there. That is the experience many people on semaglutide describe, and it is not a placebo effect. It reflects a measurable change in how the brain processes hunger.

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after eating. It travels to receptors in the hypothalamus, the brain region that governs appetite, and dials down the signals driving you to eat more. Semaglutide is a synthetic version of GLP-1, engineered to resist the enzymes that normally break the natural hormone down within minutes. Because the medicine lingers for roughly a week, those appetite-reducing signals stay active far longer than anything your body produces on its own.

Gastric emptying slows at the same time. Food moves from the stomach into the small intestine more gradually, extending the physical sensation of fullness. If you are curious about how semaglutide causes weight loss at each step of this process, the hormonal and mechanical effects are explained in detail, covering why people tend to eat less at each meal and feel satisfied sooner. Over weeks, that consistent reduction in energy intake is what drives the weight change seen in trials. You can read more about the relationship between semaglutide and weight loss and the evidence behind the results.

It is worth noting that this is a biological mechanism acting on systems that have long resisted conscious effort, which is one reason obesity guidelines now treat it as a medical condition rather than a behavioural failure.

What the GLP-1 pathway actually does at each step

GLP-1 receptors are not only in the hypothalamus. They sit in the brainstem, the vagus nerve, and the pancreas, and each location plays a role in weight regulation. In the pancreas, GLP-1 signalling increases insulin release in response to food and suppresses glucagon, the hormone that raises blood glucose. For people with type 2 diabetes this matters directly, but even in people without diabetes the improved glucose handling reduces the spikes and crashes that can trigger cravings.

The brainstem connection is particularly relevant to the nausea some people experience when starting treatment. The area postrema (the brain's nausea centre) is rich in GLP-1 receptors, and stimulating them can provoke queasiness, especially at higher doses or during dose increases. This is not a sign the medicine is harming you; it is the same receptor doing two things at once. Starting at 0.25 mg and increasing gradually gives the body time to adjust. The full Wegovy product overview covers the dose escalation schedule and what to expect during it.

The vagus nerve carries signals between gut and brain in both directions. Semaglutide activates vagal pathways that reinforce the sense of satiety, adding a physical signal on top of the hormonal one. The combined effect on the brain's reward system also appears to reduce the hedonic pull of food, the impulse to eat for pleasure rather than hunger. Clinical researchers describe this as a shift in the "food noise" many people with obesity report living with constantly. The overview of semaglutide explores the full pharmacology in more detail, including how oral and injectable forms differ in absorption.

What the trial evidence shows, and how it translates to real life

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity to 2.4 mg weekly semaglutide or placebo over 68 weeks, with both groups receiving lifestyle support. The semaglutide group lost an average of around 15% of body weight. The placebo group, on identical lifestyle advice, lost around 2.4%. The gap isolates the pharmacological effect from motivation or diet changes alone.

For the oral formulation, the OASIS 4 trial reported an average weight loss of around 13.6% at 64 weeks, rising to about 17% among participants who remained fully adherent to treatment, a distinction worth keeping in mind when reading headline figures. The NHS medicines page for semaglutide provides a clear, patient-focused account of how the medicine works and what side effects to expect.

In practice, results vary. A person's starting weight, metabolic profile, how consistently they inject, and whether they make any dietary changes all influence outcomes. Semaglutide is not a standalone solution; clinical trials pair it with a reduced-calorie diet and increased activity, and prescribers discuss that context during assessment. The medicine does the pharmacological heavy lifting (it reduces appetite reliably) but lifestyle context shapes how far the weight change goes. If you want to understand why semaglutide produces weight loss at the biological level, that question is explored separately.

One thing many people find helpful to know before their first injection: you do not need to feel significantly different from day one. The appetite change often becomes noticeable during the second or third week, once the medicine has reached steady state. Give it time, the biology is working whether or not you can feel it yet. For a broader look at the options available, the weight-loss treatments overview sets out how semaglutide sits alongside other licensed approaches.

Who semaglutide is licensed to treat (and how a clinical assessment works

Wegovy (semaglutide 2.4 mg injection) is licensed in the UK for adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition) such as high blood pressure, high cholesterol or type 2 diabetes, is present. Lower thresholds apply for some ethnic backgrounds under UK guidance. None of that automatically means it is suitable for a given individual. A prescriber looks at the full picture: other medicines, medical history, contraindications, and the person's goals.

Semaglutide is not recommended during pregnancy, whilst breastfeeding, or when trying to conceive. It is not licensed for under-18s. People with a history of pancreatitis or medullary thyroid carcinoma will need specialist discussion before a prescriber could consider it. The evidence page on Wegovy's results goes into more detail on who saw the greatest benefit in trials.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally. There is no automated approval. The assessment happens the same day, and if treatment is appropriate, the medicine is dispatched with free next-working-day delivery. The prescriber considers everything relevant, and if it is not the right treatment for you, they will say so. If you have already been reading around and want to know what the consultation involves, check your eligibility here.